| Title |
Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, February 2018
|
| DOI | 10.2147/ndt.s157099 |
| Pubmed ID | |
| Authors |
Junsheng Fan, Tszhei Fong, Xinjie Chen, Chuyun Chen, Peng Luo, Haiting Xie |
| Abstract |
Glia maturation factor-β (GMFB) is considered to be a growth and differentiation factor for both glia and neurons. GMFB has been found to be upregulated in several neuroinflammation and neurodegeneration conditions. It may function by mediating apoptosis and by modulating the expression of superoxide dismutase, granulocyte-macrophage colony-stimulating factor, and neurotrophin. In this review, we mainly discussed the role of GMFB in several neuroinflammatory and neurodegenerative diseases. On review of the literature, we propose that GMFB may be a promising therapeutic target for neuroinflammatory and neurodegenerative diseases. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 19% |
| Student > Ph. D. Student | 6 | 14% |
| Researcher | 5 | 12% |
| Student > Bachelor | 4 | 10% |
| Student > Doctoral Student | 4 | 10% |
| Other | 7 | 17% |
| Unknown | 8 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 8 | 19% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Agricultural and Biological Sciences | 4 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Unspecified | 3 | 7% |
| Other | 8 | 19% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2018.
All research outputs
#20,663,600
of 25,382,440 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,328
of 3,131 outputs
Outputs of similar age
#343,060
of 448,849 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#61
of 84 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,849 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.